Patients with T@-@ , N@/Nx , M@ prostate cancer or T@-@ disease with either prostate-specific antigen ( PSA ) of more than @ g/L or PSA of @ to @ g/L plus Gleason score of @ to @ were randomly assigned to lifelong ADT alone or to ADT+RT .